Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer

CONCLUSIONS: Comparison between the Illumina and Myriad assays showed that overall HRD status, the individual components of BRCA analysis, and HRD GIS detection results were highly concordant (>93%), suggesting the TSO 500 HRD assay will approach the analytical accuracy of the FDA-approved Myriad assay.PMID:38290412 | DOI:10.1016/j.ygyno.2024.01.016

Source: Gynecologic Oncology - January 30, 2024 Category: Cancer & Oncology Authors: Amy K Wehn Ping Qiu Jared Lunceford Alexander Yarunin Razvan Cristescu Li Liu Kyria Roessler Sven Bilke John R Day Kirsten M Timms Wilko Weichert Matthew J Marton Source Type: research